New glucocorticoids on the horizon: Repress, don't activate!

Journal of Rheumatology

Volumn 32, Issue 7, 2005, Pages 1199-1207

  Song, In Ho ^a   Gold, Ralf ^b   Straub, Rainer H ^c   Burmester, Gerd Rüdiger ^a   Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Genomic and nongenomic mechanisms cytosolic and membrane bound glucocorticoid receptor; Glucocorticoids; Nitric oxide; Transactivation; Transrepression

Indexed keywords

21 AMINOSTEROID; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; A 276575; A 27675; AL 438; APOLIPOPROTEIN A1; CYCLOOXYGENASE 2; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE 21 [(4' NITROOXY)BUTYRATE]; I KAPPA B; LIGAND; LIPOCORTIN 1; LONG CIRCULATING LIPOSOMAL GLUCOCORTICOID; N [3 [BENZYL(4 CHLORO 2 FLUOROBENZYL)AMINO] 2 METHYLPHENYL]METHANESULFONAMIDE; NCX 1004; NCX 1015; NITROSTEROID; PREDNISOLONE; PREDNISOLONE 21 [(4' NITROOXYMETHYL)BENZOATE]; RU 24782; RU 24858; RU 40066; SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST; SELECTIVE GLUCOCORTICOID RECEPTOR MODULATING AGENT; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; COLLAGEN DISEASE; CUSHING DISEASE; EYE DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MEMBRANE BINDING; MYOPATHY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; STEROID THERAPY;

ANIMALS; DRUG DESIGN; GLUCOCORTICOIDS; HUMANS; RHEUMATIC DISEASES;

EID: 22244487282     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23.
2. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 1994;21:1207-13.
3. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
4. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990;112:352-64.
5. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993;119:963-68.
6. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989;30:135-9.
7. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988;4:17-30.
8. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
9. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression activity by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101:227-32.
10. Perretti M, Paul-Clark MJ, Mancini L, Flower RJ. Generation of innovative anti-inflammatory and anti-arthritic glucocorticoid derivatives that release NO: the nitro-steroids. Dig Liver Dis 2003;35 Suppl 2:41-8.
11. Schmidt J, Metselaar JM, Wauben MH, et al. Drug targeting by long circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003;126:1895-904.
12. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94:557-72.
13. Adcock IM. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther 2000;13:115-26.
14. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002; 71:9-15.
15. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid action. Arthritis Rheum 1998;41:761-7.
16. Yang-Yen HF, Chambard JC, Sun YL, et al. Transcriptional interference between c-jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990;62:1205-15.
17. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994;91:752-6.
18. Belvisi MG, Brown TJ, Wicks S, Foster ML. New glucocorticosteroids with an improved therapeutic ratio. Pulm Pharmacol Ther 2001;14:221-7.
19. Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001;20:7168-73.
20. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kappa B activation and function by glucocorticoids. J Mol Endocrinol 2002;28:69-78.
21. Caldenhoven E, Liden J, Wissink S, et al. Negative crosstalk between RelA and the glucocorticoid receptor. A possible mechanism for the anti-inflammatory action of glucocorticosteroids. Mol Endocrinol 1995;9:401-12.
22. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-41.
23. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticosteroids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol 1997;11:1245-55.
24. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001;166:1975-82.
25. Tanigawa K, Tanaka K, Nagase H, et al. Cell type-dependent divergence of transactivation by glucocorticoid receptor ligand. Biol Pharm Bull 2002;25:1619-22.
26. Lin CW, Nakane M, Stashko M, et al. trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-yl) -1H-[1]benzopyrano [3,4-f]quinoline (A276575) and its four stereoisomers. Mol Pharmacol 2002; 62:297-303.
27. Ali A, Thompson CF, Balkovec JM, et al. Novel N-Arylpyrazolo [3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity. J Med Chem 2004;47:2441-52.
28. Miner JN. Designer glucocorticoids. Biochem Pharmacol 2002;64:355-61.
29. Coghlan MJ, Jacobson PB, Lane B, et al. A novel anti-inflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 2003;17:860-9.
30. Link JT, Sorensen BK, Lai C, et al. Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids. Bioorg Med Chem Lett 2004;14:4173-8.
31. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
32. Paul-Clark MJ, Gilroy DW, Willis D, Willoughby DA, Tomlinson A. Nitric oxide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration. J Immunol 2001;166:1169-77.
33. Gaboury JP, Niu XF, Kubes P. Nitric oxide inhibits numerous features of mast cell-induced inflammation. Circulation 1996;93:318-26.
34. Park SK, Lin HL, Murphy S. Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappa B binding to DNA. Biochem J 1997;322:609-13.
35. Katsuyama K, Shichiri M, Marumo F, Hirata Y. NO inhibits cytokine-induced iNOS expression and NF-kappa B activation by interfering with phosphorylation and degradation of I kappa B-alpha. Arterioscler Thromb Vasc Biol 1998;18:1796-802.
36. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol 2001;166:3873-81.
37. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995;96:2711-8.
38. Paul-Clark M, Del Soldato P, Fiorucci S, Flower RJ, Perretti M. 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol 2000;131:1345-54.
39. Paul-Clark MJ, Mancini L, Del Soldato P, Flower RJ, Perretti M. Potent and arthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci USA 2002;99:1677-82.
40. Fiorucci S, Santucci L, Antonelli E, et al. A new nitric oxide steroid derivative (NCX 1015) with enhanced anti-inflammatory properties reduces colonic inflammation in mice [abstract]. Gastroenterology 2000;118:3049A.
41. Tallet D, Del Soldato P, Oudart N, Burgaud JL. NO-Steroids: potent anti-inflammatory drugs with bronchodilating activity in vitro. Biochem Biophys Res Commun 2001;290:125-30.
42. Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des 2002;8:201-13.
43. Wainwright C, Miller AM, Work LM, Del Soldato P. NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischemia/reperfusion in pigs. Br J Pharmacol 2002;135:1882-8.
44. Napoli C, Ackah E, de Nigris F, et al. Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc Natl Acad Sci USA 2002;17:12467-70.
45. Napoli C, Aldini G, Wallace JL, et al. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci USA 2002;99:1689-94.
46. Fiorucci S, Del Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 2003;35 Suppl 2:9-19.
47. Moore PK, Marshall M. Nitric oxide releasing acetaminophen (nitroacetaminophen). Dig Liver Dis 2003;35 Suppl 2:49-60.
48. Fiorucci S, Antonelli E, Burgaud JL, Morelli A. Nitric oxide-releasing NSAIDs: a review of their current status. Drug Saf 2001;24:801-11.
49. Wallace JL. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease. Dig Liver Dis 2003;35 Suppl 2:35-40.
50. Fiorucci S, Antonelli E, Morelli A. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. Dig Liver Dis 2003;35 Suppl 2:61-9.
51. Rigas B, Kalofonos H, Lebovics E, Vagenakis AG. NO-NSAIDS and cancer: promising novel agents. Dig Liver Dis 2003;35 Suppl 2:27-34.
52. Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 2000;21:192-9.
53. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002;67:529-34.
54. Falkenstein E, Norman AW, Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab 2000;85:2072-5.
55. Cato ACB, Nestl A, Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002;138:RE9.
56. Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling actors to activated EOF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000;130:289-98.
57. Hafezi-Moghadam A, Simoncini T, Yang E, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8:473-9.
58. Buttgereit F, Hiepe F, Burmester GR. The therapeutic potential of lazaroids (21-aminosteroids). A recent study. Dtsch Med Wochenschr 1997;122:1363-7.
59. Braughler JM, Pregenzer JF. The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxy radicals. Free Radic Biol Med 1989;7:125-30.
60. Dissemond J, Schneider LA, Wlaschek M, Brauns TC, Goos M, Scharfetter-Kochanek K. The lazaroid tirilazad is a new inhibitor of direct and indirect UVA-induced lipid peroxidation in human dermal fibroblasts. Arch Dermatol Res 2003;295:287-92.
61. Bath PM, Iddenden R, Bath FJ, Orgogozo JM. Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev 2001;4:CD002087.
62. Dorsch NW, Kassell NF, Sinkula MS. Metaanalysis of trials of tirilazad mesylate in aneurysmal SAH. Acta Neurochir Suppl 2001;77:233-5.
63. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001;18:685-716.
64. Bangham AD, Home RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964;8:660-8.
65. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99.
66. Oku N, Namba Y. Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst 1994;11:231-70.
67. Woodle MC, Newman MS, Cohen JA. Sterically stabilized liposomes: physical and biological properties. J Drug Target 1994;2:397-403.
68. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
69. Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001;91:1826-33.
70. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999;37:225-35.
71. Dams ET, Oyen WJ, Boerman OC, et al. 99mTc-PEG liposomes for the detection of infection and inflammation: clinical evaluation. J Nucl Med 2000;41:622-30.
72. Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka HV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000;123:1431-41.
73. Schmidt J, Sturzebecher S, Toyka KV, Gold R. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res 2001;65:59-67.
74. Zettl UK, Gold R, Toyka KV, Hartung HP. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol 1995;54:540-7.
75. Metselaar JM, Wauben MH. Wagenaar-Hilbers JP, Boermann OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003;48:2059-66.
76. Metselaar JM, van den Berg WB, Holthuysen AE, Wauben MH, Storm G, van Lent PL. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 2004;63:348-53.
77. Bodor N. Retrometabolic drug design -novel aspects, future directions. Pharmazie 2001;56:S67-S74.
78. Belvisi MG, Hele DJ. Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 2003;16:321-5.
79. Szelenyi I, Hermann R, Petzold U, Pahl A, Hochhaus G. Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate. Pharmazie 2004;59:409-11.
80. Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991;252:1848-51.
81. Gametchu B, Watson CS, Wu S. Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukaemic patients. FASEB J 1993;7:1283-92.
82. Chen F, Watson CS, Gametchu B. Association of the glucocorticoid receptor alternatively-spliced transcript IA with the presence of the high molecular weight membrane glucocorticoid receptor in mouse lymphoma cells. J Cell Biochem 1999;74:430-46.
83. Sackey FN, Watson CS, Gametchu B. Cell cycle regulation of membrane glucocorticoid receptor in CCRF-CEM human ALL cells: correlation to apoptosis. Am J Physiol 1997;273:E571-83.
84. Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004;18:70-80.